Hikma Proves Resilient In 2020 Despite Some Bumpy Launches
Rivals To Advair And Vascepa Suffer From Delays And API Scarcity
Executive Summary
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
You may also be interested in...
Ups And Downs See Mid-Table Players Shift Position
Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.
Hikma Is Taking Another Look At US Biosimilars
Hikma CEO Siggi Olafsson has outlined the potential future opportunity that the firm sees in the US biosimilars market, in the second part of an exclusive interview with Generics Bulletin.
Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.